Print

Active Biotech AB - Interim report January - June 2017

2017-08-10


Second quarter in brief

  • In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma
  • The primary clinical endpoint from the Phase III trial of laquinimod in RRMS (CONCERTO study) was not met. The secondary endpoints (brain atrophy, relapse rate and MRI-data) were achieved and in line with previous studies
  • Out-licensing activities are continuing for tasquinimod, paquinimod and SILC

Events after the end of the period

  • Helén Tuvesson succeeds Tomas Leanderson as President & CEO of the company July 1, 2017
  • In July, a patent application for the use of ANYARA in combination with PD-1 inhibitors for the treatment of cancer was published on WIPO's (World Intellectual Property Organization) website www.wipo.int

Financial summary

SEK M April-June Jan.-June Full-year
2017 2016 2017 2016 2016
Net sales 5.1 3.9 9.8 7.9 19.0
Operating loss -23.1 -14.5 -37.7 -30.6 -55.1
Loss for the period -24.4 -15.5 -40.2 -32.3 -59.6
Loss per share, before and after dilution (SEK) -0.25 -0.17 -0.42 -0.36 -0.65
Cash and cash equivalents (at the end of the period) 47.7 57.4 77.7

For further information, please contact:

Helén Tuvesson, President & CEO
Tel: +46 (0)46-19 21 56



Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: 046 (0)46-19 20 00

The report is also available at www.activebiotech.com.


pdfActive Biotech AB - Interim report January – June 2017



Back